Privacy voorkeur

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


ESMO 2017 in-depth: RANGE trial

This year the ESMO congress took place in Madrid from 8 - 12 September. Daniel Petrylak, Professor of Medicine and Urology at Yale School of Medicine, explains the design and results of the RANGE trial. This phase III randomised trial evaluated the efficacy of ramucirumab in combination with docetaxel in patients with advanced urothelial cancer who failed prior platinum-based therapy.

  • This program is editorially independent and is financially made possible by

Related items

Congress news

ESMO 2017 in-depth: Neoadjuvant chemotherapy in cervical cancer

This year the ESMO congress took place in Madrid from 8 - 12 September. Sudeep Gupta, Professor of Medical Oncology at Tata Memorial Hospital in Mumbai, explains the design and results of his trial, that examined whether neoadjuvant chemotherapy followed by surgical removal of the tumour could improve outcomes in patients with locally advanced cervical cancer compared to standard treatment with chemoradiation.

Congress news

Oncology News Program at Genitourinary Cancers Symposium 2015

The 2015 Genitourinary Cancers Symposium was held in Orlando from February 26th to 28th. In a multidisciplinary Oncology News Program Dutch and Belgian experts will discuss new important data, presented at this congress. In the first part of this Oncology News Program Dr. Thierry Gil, Prof. Jeroen van Moorselaar and Dr. Fons van den Bergh talk about the role of Androgen Deprivation Therapy in early and intermediate risk prostate cancer, dose escalation in Radiotherapy, Stereotactic Body Radiotherapy and possible predictive markers like Slco2B1 and androgen receptor splice variant 7. The second part covers the following topics on prostate cancer: Active Surveillance in early stage prostate cancer, Brachytherapy versus External Beam Radiation Therapy, active immunotherapy and check point inhibitors and one of the highlights of this congress, the GETUG-15 trial. These data are discussed by Prof. Winald Gerritsen, Prof. Gert De Meerleer and Prof. Thierry Roumeguère. The panel for the last part of this Oncology News Program consists of Prof. Gerritsen, Prof. van Moorselaar and Prof. Roumeguère. The experts discuss important new data on GU-non prostate cancer: organ sparing versus radical cystectomy, (neo)adjuvant chemotherapy in bladder cancer, the role of profiling urothelial cancer, anti-PDL1 and Pazopanib in combination with Paclitaxel in refractory urothelial cancer. Presented by dr. Ayan Panja.

Congress news

ESMO 2017 in-depth: TONIC trial

This year the ESMO congress took place in Madrid from 8 - 12 September. Marleen Kok, MD, PhD at The Netherlands Cancer Institute in Amsterdam, explains the design and first results of the TONIC trial. This adaptive phase II trial evaluated the response rate to nivolumab after induction treatment in patients with triple-negative breast cancer.

Congress news

ESMO 2017 in-depth: KEYNOTE-040 trial

This year the ESMO congress took place in Madrid from 8 - 12 September. E. This phase III trial evaluated the efficacy of checkpoint inhibitor pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma after platinum-based chemotherapy.

Congress news

ASCO GU 2017: Discussion program on prostate and bladder cancer

On February 16-18, the 2017 Genitourinary Cancers Symposium took place in Orlando, Florida. An international multidisciplinary panel discussed a selection of topics and new data on prostate and bladder cancer. During a live connection, questions were submitted by participants of the ASCO Direct GU Virtual meetings in 7 different countries (Austria, Belgium, Brazil, Germany, Netherlands, United Arabic Emirates and Switzerland) Topics: Active surveillance in localized prostate cancer Impact of ProtecT trial results Value of imaging, genomics, and genetics for active surveillance High-risk prostate cancer, definition and therapeutic controversies Value of chemoradiation for bladder cancer Molecular predictors and response to neoadjuvant chemotherapy in bladder cancer Speakers: Prof. Bertrand Tombal MD PhD, urologist, Université catholique de Louvain, Cliniques universitaires Saint-Luc, Brussels, Belgium Prof. Robert Bristow MD PhD, radiation oncologist, Princess Margaret Hospital, Toronto, Canada Prof. Thomas Bauernhofer MD, medical oncologist, University Clinic for Internal Medicine Karl-Franzens University, Graz, Austria Neil Shore MD, urologist, Atlantic Urology Clinic, Myrtle Beach, USA Moderator: Catherine Hood PhD  

Congress news

​ASCO GU 2017: Atezolizumab in mUCC

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Daniel Petrylak Poster: B290 - Atezolizumab (atezo) in patients with metastatic urothelial carcinoma (mUC): A 2-year clinical update from a phase Ia study

Congress news

​ASCO GU 2017: Durvalumab in advanced UCC

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Thomas Powles Poster: B286 - Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.